Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy

Journal of the National Cancer Institute

Volumn 106, Issue 11, 2014, Pages

  Parra Palau, Josep Lluís ^a   Morancho, Beatriz ^a   Peg, Vicente ^b   Escorihuela, Marta ^a   Scaltriti, Maurizio ^c   Vicario, Rocio ^a   Zacarias Fluck, Mariano ^a   Pedersen, Kim ^a   Pandiella, Atanasio ^d   Nuciforo, Paolo ^a   Serra, Violeta ^a   Cortés, Javier ^a   Baselga, José ^c   Perou, Charles M ^e   Prat, Aleix ^a   Rubio, Isabel T ^a   Arribas, Joaquín ^a,f,g  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d Salamanca Spain   (Spain)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CTF PROTEIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; LAPATINIB; MESSENGER RNA; PROTEIN; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ERBB2 PROTEIN, MOUSE; MONOCLONAL ANTIBODY; TAXOID;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; CELL PROLIFERATION; CONFOCAL MICROSCOPY; DRUG EFFECTS; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; METABOLISM;

ANIMALS; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL PROLIFERATION; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICROSCOPY, CONFOCAL; RECEPTOR, ERBB-2; TAXOIDS; TRASTUZUMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84984985644     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju291     Document Type: Article

References (18)

1. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96(10):739-749.
2. Gradishar WJ. HER2 therapy-An abundance of riches. N Engl J Med. 2012;366(2):176-178.
3. Arribas J, Baselga J, Pedersen K, Parra-Palau JL. p95HER2 and breast cancer. Cancer Research. 2011;71(5):1515-1519.
4. Scaltriti M, Rojo F, Ocaña A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8):628-638.
5. Pedersen K, Angelini PD, Laos S, et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol. 2009;29(12):3319-3331.
6. Parra-Palau JL, Pedersen K, Peg V, et al. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers. Cancer Research. 2010;70(21):8537-8546.
7. Sperinde J, Jin X, Banerjee J, et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumabtreated breast cancer patients. Clin Cancer Res. 2010;16(16):4226-4235.
8. Loibl S, Bruey J, Minckwitz Von G, et al. Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study. J Clin Oncol. 2011;29(suppl):Abstract 530.
9. Prat A, Bianchini G, Thomas M, et al. Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study. Clin Cancer Res. 2014;20(2):511-521.
10. Fasching PA, Heusinger K, Haeberle L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11(1):486.
11. Morancho B, Parra-Palau JL, Ibrahim YH, et al. A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. Oncogene. 2013;32(11):1452-1459.
12. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004;10(17):5650-5655.
13. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Medicine. 2000;6(4):443-446.
14. Piloto O, Levis M, Huso D, et al. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. Cancer Research. 2005;65(4):1514-1522.
15. Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009;28(6):803-814.
16. Scaltriti M, Nuciforo P, Bradbury I, et al. High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib. 36th San Antonio Breast Cancer Symposium; 2013:Poster P1-08-42.
17. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-Approved scoring system. J Clin Oncol. 1999;17(7):1983-1987.
18. Parker JS, Mullins M, Cheang MCU, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J Clin Oncol. 2009;27(8):1160-1167.